Efficacy of targeted therapy in patients with HER2-positive non-small cell lung cancer: A systematic review and meta-analysis

Hong-Xia Wu | Kai-Quan Zhuo | Ke Wang

1Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China
2Department of Neurosurgery, Suining Municipal Hospital of TCM, Suining, China

Correspondence
Prof. Ke Wang, MD, Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China. No. 37 Guoxue Alley, Chengdu, Sichuan, 610041, China. Email: 442620720@qq.com

Funding information
National Natural Science Foundation of China, Grant/Award Numbers: 82070019, 81870034

Anti-human epidermal growth factor receptor 2 (HER2) therapy is an effective treatment for HER2-positive gastric and breast malignancies. However, the efficacy of HER2-targeted therapy in non-small cell lung cancer (NSCLC) patients with HER2 alterations remains controversial. We searched studies on HER2-targeted therapy in NSCLC patients that reported objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS) published from database inception to 30 May 2021. A total of 32 trials involving 958 patients were included. The ORRs of HER2-TKIs targeted therapy, humanised monoclonal antibody, trastuzumab-based treatment and antibody-drug conjugate (ADC) (T-DM1) were 22% (95% CI 11–31), 23% (95% CI 20–65), 26% (95% CI 14–39) and 16% (95% CI 6–37), while that of ADC (DS-8201) was 60% (95% CI 35–85). The DCRs of these groups were 59% (95% CI 49–69), 39% (95% CI 9–88), 63% (95% CI 37–89), 31% (95% CI 4–58) and 87% (95% CI 62–112), respectively. In the subgroup analysis, numerically higher ORRs and DCRs were observed in the poziotinib (38%; 75%) and pyrotinib (35%; 83%) groups. The median PFSs of these groups were 5.51 months, 3.09 months, 4.61 months, 2.65 months and 12.04 months, respectively. HER2-targeted therapy can be considered an acceptable treatment strategy for NSCLC patients with HER2 alterations. In particular, ADC (DS-8201), pyrotinib and poziotinib demonstrated promising anti-tumour activity in HER2-positive NSCLC.

KEYWORDS
biomarkers, ERBB2, HER2, meta-analysis, non-small cell lung cancer, review, targeted therapy

1 | INTRODUCTION

Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancers.1 NSCLC is one of the most genomically diverse cancers, making it very difficult to treat. For all NSCLC patients who have the adenocarcinoma subtype, testing for alterations in epidermal growth factor receptor (EGFR), mesenchymal epithelial transition factor (MET), b-raf proto-oncogene (BRAF), anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), ret proto-oncogene (RET) and neurotrophic tyrosine receptor kinase (NTRK) is recommended by the National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) guidelines.2,3

Received: 14 September 2021 Revised: 9 October 2021 Accepted: 9 November 2021
DOI: 10.1111/bcp.15155
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Human epidermal growth factor receptor 2 (HER2) is a member of the ERBB receptor tyrosine kinase family. HER2 mutations are commonly found in never-smokers and adenocarcinoma. HER2 alterations, including gene amplification, mutations and overexpression, have also been found in many other cancers and are associated with poor clinical prognoses. The frequency of HER2 alterations varies according to the detection methods used, tumour biology, and heterogeneity. In lung cancer, 2–6% HER2 mutations have been detected by polymerase chain reaction (PCR) or next-generation sequencing (NGS). 2–20% HER2 amplification was detected by NGS or fluorescence in situ hybridisation (FISH). 2–38% HER2 protein was detected by immunohistochemistry (IHC), but IHC 3+ was found only in 2–6% of patients. These three HER2 alterations are correlated with the clinical efficacy of HER2-targeted therapy. Thus, HER2 alterations are considered as independent biomarkers for HER2-targeted therapy.

Current HER2-targeted medicines, including tyrosine kinase inhibitors (TKIs), monoclonal antibodies and antibody-drug conjugates (ADC), have been developed for breast and gastric adenocarcinoma patients with HER2 amplification and protein overexpression. To allow clarity and consistency in pharmacology, the nomenclature of HER2-targeted drugs conforms to the IUPHAR/BPS Guide to Pharmacology. TKIs, including afatinib, lapatinib, poziotinib, pyrotinib, neratinib, dacomitinib, tucatinib and tarloxitinib, bind to the intracellular domain of HER2. On the other hand, monoclonal antibodies and ADC, such as pertuzumab, trastuzumab, trastuzumab deruxtecan and ado-trastuzumab emtansine, bind to the extracellular domain of HER2. There is no association between HER2 overexpression, mutations and amplification, which makes evaluating the efficacy of HER2-targeted medicines difficult. Nonetheless, evaluating the efficacy of such therapies is important in optimising cancer treatment. This study aimed to investigate the efficacy of targeted therapy in HER2-positive NSCLC patients.

2 | METHODS

2.1 | Search strategy

We searched multiple databases, including Web of Science, Embase, Medline and Cochrane, for trials using the terms “[HER2(Title/Abstract)] OR [ERRB (Title/Abstract)] AND [non-small cell lung cancer (Title/Abstract)] OR [NSCLC (Title/Abstract)]” with no restrictions in the publication language or period. We searched for reports published from database inception to May 30, 2021. We also retrieved the references of all the included studies to minimise error and bias. Keywords in related conference articles were also used to retrieve the studies. The results were recorded according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. This study was registered with PROSPERO (number CRD42021257794). The following clinical trials were eligible: (1) randomised controlled trials (RCTs), single-arm and cohort studies; (2) trials conducted in HER2-positive patients with NSCLC; and (3) trials reporting data on the objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS). Patients were excluded if they had received chemotherapy, surgery, radiotherapy anti-HER2 therapy, or other targeted therapies within four weeks before the first dose of the medication of interest. Patients admitted for other medical problems were excluded. Trials on pregnant women, reviews, editorials, case reports, congress articles and articles unrelated to our theme were omitted. The outcome measures were the ORR, DCR and PFS in patients with NSCLC treated with HER2-targeted therapy.

2.2 | Study selection

Hong-Xia Wu and Kai-Quan Zhuo performed the study selection. First, the abstract and titles were examined, and duplicates and unavailable full-text articles were discarded. Next, qualified trials were selected by screening the full texts. The reasons for exclusion were documented. A third reviewer (Ke Wang) was consulted if no consensus was reached.

2.3 | Data extraction

Hong-Xia Wu and Kai-Quan Zhuo independently extracted and recorded the demographic characteristics and outcome measures of each study in a standard form advised by Cochrane. The corresponding authors were emailed if any information was missing.

2.4 | Quality assessment

The Cochrane Risk of Bias tool was used to assess the quality of the studies. The quality of non-randomised studies was evaluated using the Newcastle–Ottawa Scale (NOS). Two investigators (Hong-Xia Wu and Kai-Quan Zhuo) conducted the quality assessment. Any disagreements were resolved by a third investigator (Ke Wang).

2.5 | Quantitative data synthesis

A random-effects model and the inverse variance heterogeneity method were used to analyse PFS and heterogeneity ($I^2$). The Mantel–Haenszel method and a random-effects model were used to analyse the ORR, DCR and $I^2$. Analyses were performed using STATA (Version 16; Stata Corp., College Station, TX, USA). The outcomes are expressed in forest plots. Dichotomous and continuous variables are shown as odds ratios (OR) and median values, respectively. $I^2 > 50\%$ was considered significant for the heterogeneity test. A fixed-effects model was used in cases of no heterogeneity; otherwise, a random-effects model was used.
3 | RESULTS

3.1 | Study selection process

A total of 116 studies were obtained by screening the abstracts. After removing duplicate records, 54 studies remained for subsequent screening. After excluding irrelevant documents, 42 studies were selected by qualification evaluation and full-text reviews. Finally, 32 studies were assessed in this meta-analysis. The details of the study selection process are presented in Figure 1.

3.2 | Characteristics of clinical trials

Thirty-two studies involving 958 patients were included in this study. Details of the study characteristics and outcomes are presented in Table 1. Among the 32 studies, there were 4 RCTs, 11 cohort studies, 17 single-arm studies, 1 phase I study and 15 phase II studies. Some trials have a relatively small population, but HER2 genomic alterations have emerged as distinct oncogenic drivers. Thus, few tests fulfilled our meta-analysis inclusion criteria. The ORR and DCR of single-arm RCTs were used and combined with data from cohort and single-arm trials.

3.3 | Quality assessment and heterogeneity

The assessment of study quality is detailed in Supplementary Figures S1 and S2 and Supplementary Table S1. No studies were excluded because of low quality. Significant statistical heterogeneity was found in the following outcomes: PFS of HER2 TKI-targeted therapy ($I^2 = 93.3\%, P = .000$) (Figure 6); ORR, DCR, and PFS of the humanised monoclonal antibody group ($I^2 = 71.6\%, P = .029; I^2 = 78.5\%, P = .009; I^2 = 93.1\%, P = .000$) (Figures 3, 5 and 7); and DCR and PFS of the trastuzumab-based treatment group ($I^2 = 66.1\%, P = .012; I^2 = 81.6\%, P = .001$) (Figures 5 and 7). A sensitivity analysis was used to assess the stability of the results (Supplementary Figures S3, S7, S11 and S15). One study was removed at a time, and the summary median/OR value and overall effect were recalculated. The absence of a statistically significant reversal of the overall effects ($I^2$) confirmed the stability of the results.

3.4 | Outcome measures

3.4.1 | ORR

The overall ORRs of HER2-TKIs targeted therapy, humanised monoclonal antibody, trastuzumab-based treatment and ADC (T-DM1)
| Classification of treatment | First author | Year | Registration number | Study design | Treatment | Population | Gene type |
|----------------------------|--------------|------|---------------------|--------------|-----------|------------|-----------|
| HER2-TKIs therapy          | Mazières et al. | 2013 | NM | Retrospective cohort study | Afatinib, Lapatinib, Masatinib | NSCLC | HER2 exon-20 insertion |
|                            | Mazières et al. | 2015 | NM | Retrospective cohort study | Neratinib, Lapatinib, Afatinib | NSCLC | HER2 exon-20 insertion |
|                            | De Grève et al. cohort 1 | 2015 | EudraCT: 2008-001546-67 | Prospective cohort study | Afatinib | Lung adenocarcinoma | HER2 mutation |
|                            | De Grève et al. cohort 2 | 2015 | EudraCT: 2008-001546-67 | Prospective cohort study | Afatinib plus Paclitaxel | Lung adenocarcinoma | HER2 mutation |
|                            | Kris et al. | 2015 | NCT0114286 | Phase II study | Dacomitinib | HER2-mutant or amplified tumours | HER2 mutation or amplification |
|                            | Song et al. | 2016 | NM | Retrospective multicentre single-arm study | Afatinib | NSCLC | HER2 exon-20 insertion |
|                            | Lai et al. | 2017 | NM | Retrospective study | Afatinib | Lung adenocarcinoma | HER2 mutation |
|                            | Gandhi et al. cohort 1 | 2017 | NCT01827267 | Randomised controlled trial | Neratinib | Lung cancers | HER2 mutation |
|                            | Gandhi et al. cohort 2 | 2017 | NCT01827267 | Randomised controlled trial | Neratinib + Temsirolimus | Lung cancers | HER2 mutation |
|                            | Oh et al. | 2018 | NCT02979821 | Retrospective study | Poziotinib or Afatinib | Lung adenocarcinoma | HER2 mutation |
|                            | Zhao et al. | 2018 | NM | Retrospective single-arm study | Afatinib | NSCLC | HER2 mutation |
|                            | Peters et al. | 2018 | NM | Retrospective single-arm study | Afatinib | Lung adenocarcinoma | HER2 exon 20 mutation |
|                            | Liu et al. | 2018 | NM | Retrospective single-arm study | Afatinib | Lung cancers | HER2 exon 20 insertiion |
|                            | Robichaux et al. | 2018 | NCT03066206 | Single-arm phase II trial | Poziotinib | NSCLC | HER2 exon 20 mutation |
|                            | Hyman et al. | 2018 | NCT01953926 | Single-arm phase II trial | Neratinib | Advanced NSCLC | HER2 mutation |
|                            | Dziadziuszek et al. | 2019 | NCT02369484 | Single-arm phase II trial | Afatinib | NSCLC | HER2 exon 20 mutation |
|                            | Robichaux et al. | 2019 | NCT03066206 | Single-arm phase II trial | Poziotinib | NSCLC | HER2 mutation |
|                            | Wang et al. | 2019 | NCT02535507 | Single-arm phase II study | Pyrotinib | NSCLC | HER2 exon 20 insertiion |
|                            | Zhou et al. | 2020 | NM | Single-arm phase II study | Pyrotinib | Lung adenocarcinoma | HER2 mutation |
|                            | Zhou et al. | 2020 | NM | Retrospective cohort study | Afatinib or Pyrotinib | Advanced lung cancers | HER2 mutation |
|                            | Liu et al. | 2020 | NCT03805841 | Cohort study | Tarloxotinib | NSCLC | HER2 mutation |
|                            | Socinski et al. | 2020 | NCT03318939 | Cohort phase II study | Poziotinib | NSCLC | HER2 exon-20 insertion |
| Classification of treatment | First author | Year | Registration number | Study design | Treatment | Population | Gene type |
|-----------------------------|--------------|------|---------------------|--------------|-----------|------------|-----------|
| Humanised monoclonal antibody | Lara et al. | 2003 | NM | Randomised controlled trial | Trastuzumab | NSCLC | HER2 protein overexpression or HER2 amplification |
| Herbst et al. | 2007 | NM | Multicentre phase II study | Pertuzumab | Advanced or metastatic NSCLC | HER2 mutation |
| Mazières et al. | 2015 | NM | Retrospective cohort study | Trastuzumab, T-DM1 | NSCLC | HER2 exon-20 insertion |
| Trastuzumab-based therapy | Lara et al. | 2003 | NM | Randomised controlled trial | Trastuzumab plus Docetaxel | Advanced, recurrent, or metastatic NSCLC | HER2 mutation |
| Langer et al. | 2004 | ECOG 2598 | Phase II trial | Trastuzumab plus Carboplatin and Paclitaxel | NSCLC | HER2 overexpression |
| Gatzemeier et al. | 2004 | NM | Randomised phase II study | Gemcitabine-cisplatin plus Trastuzumab | NSCLC | HER2-positive |
| Mazières et al. | 2013 | NM | Retrospective cohort study | Trastuzumab in combination with chemotherapy | NSCLC | HER2 exon-20 insertion |
| Hainsworth et al. | 2018 | NCT02091141 | Phase II study | Trastuzumab plus Pertuzumab | NSCLC | HER2 mutation, amplification, or overexpression |
| de Langen et al. | 2018 | NCT02226757 | Single-arm phase II study | Trastuzumab and Paclitaxel | Non-squamous NSCLC | HER2 overexpression |
| Zhou et al. | 2020 | NM | Retrospective cohort study | Trastuzumab-based therapy | Advanced lung cancers | HER2 mutation |
| Li et al. | 2021 | NCT01953926 | Phase II study | Neratinib plus Trastuzumab | NSCLC | HER2 mutation |
| Antibody drug conjugate, DS-8201 | Smit et al. | 2020 | NCT03505710 | Multicentre phase II study | Trastuzumab deruxtecan (DS-8201) | NSCLC | HER2 mutation |
| | Tsunutani et al. | 2020 | NCT02564900 | Phase I study | Trastuzumab deruxtecan (DS-8201) | NSCLC | HER2 overexpression, or mutation |
| Antibody drug conjugate, T-DM1 | Hotta et al. | 2017 | NM | Randomised controlled trial | Trastuzumab emtansine (T-DM1) | Adenocarcinomas | HER2 overexpression |
| Li et al. | 2018 | NCT02675829 | Phase II basket trial | Ado-trastuzumab emtansine | Lung cancers | HER2 mutation, overexpression or amplification |
| Peters et al. | 2019 | NCT02289833 | Prospective multicentre single-arm study | Trastuzumab Entansine (T-DM1) | NSCLC | HER2 overexpression |

Total 32 studies

Abbreviations: NM, not mentioned; NSCLC, non-small cell lung carcinoma; ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival; ARMS-PCR: amplification refractory mutation system-polymerase chain reaction; PCR, polymerase chain reaction; NGS, next generation sequencing; FISH, fluorescent in-situ hybridisation; CISH, chromogenic in-situ hybridisation; ICH, immunohistochemistry; ELISA, enzyme-linked immunosorbent assay.
| Classification of treatment | Number of patients | Outcomes | Country | Male (%) | Age, median (range) | Never-smokers (%) | Molecular diagnostics | Tumour stage |
|-----------------------------|--------------------|----------|---------|----------|---------------------|-------------------|----------------------|--------------|
| HER2-TKIs therapy          | 4                  | ORR, DCR | France, Germany, Switzerland and Spain | 31       | 60.4 (31–86)       | 52.3              | Direct sequencing or FISH | I-IV         |
|                             | 29                 | ORR, DCR, PFS | France, Switzerland, Spain, Italy, Poland, Portugal and the Netherlands | 37.6     | 61 (30–87)         | 60.4              | PCR or NGS           | I-IV         |
|                             | 7                  | ORR, DCR | Belgium, Spain, United Kingdom and United States | 0        | 62 (50–79)         | 71                | FISH                 | IIIB/IV      |
|                             | 3                  | ORR, DCR | Belgium, Spain, United Kingdom and United States | 0        | 62 (50–79)         | 71                | FISH                 | IIIB/IV      |
|                             | 30                 | ORR, DCR | United States, China and Japan | 50       | 58.7 (37–74)       | 60                | FISH or sequencing by multiplexed testing | IIIB-IV      |
|                             | 4                  | DCR, PFS | China | 33.3     | 60 (39–70)         | 81                | NGS                  | I-IV         |
|                             | 23                 | ORR, DCR | Europe, Australia and North America | 59       | 63 (40–84)         | 67                | PCR or NGS           | IV or recurrent |
|                             | 17                 | ORR, DCR | NM | 32       | 66                  | 60                | NM                   | IIIB/IV      |
|                             | 43                 | ORR, DCR | NM | 32       | 66                  | 60                | NM                   | IIIB/IV      |
|                             | 7                  | ORR, DCR | Korea | 0        | 48.5 (55–61)       | 100               | NGS                  | I-IV         |
|                             | 23                 | ORR, PFS | China | NM         | NM                  | NM                | NGS                  | NM          |
|                             | 16                 | ORR, DCR | Switzerland, Israel, Taiwan, Slovenia, Austria and United States | 43       | 55 (39–93)         | NM                | NM                   | IV          |
|                             | 19                 | ORR, DCR | China | 37       | 57 (41–86)         | NM                | NGS                  | NM          |
|                             | 11                 | ORR, DCR | United States | NM         | 57.6 (52–66)       | NM                | PCR-based NGS       | NM          |
|                             | 26                 | ORR, DCR | United States, Spain and Australia | 34.6     | 62 (46–74)         | NM                | DNA sequencing       | NM          |
|                             | 13                 | ORR, DCR, PFS | Poland, Netherlands, Greece, Germany, Ireland Switzerland and Spain | 30.8     | 59 (39–82)         | 61.5              | NM                   | IIIB/IV      |
|                             | 12                 | ORR, DCR | United States | 16.7       | 59.5 (56.5–61)     | NM                | NM                   | NM          |
|                             | 15                 | ORR, DCR, PFS | China | 53       | 58 (42–78)         | 67                | ADx HER2 Mutation Detection Kit, ARMS, NGS, or DNA direct sequencing | NM          |
|                             | 60                 | ORR, DCR | China | 45       | 57 (40–72)         | 71.7              | NGS or ADx HER2 Mutation Detection Kit | IIIB/IV      |
|                             | 25                 | ORR, DCR, PFS | China | 45       | 56 (32–76)         | 73                | ARMS-PCR or PCR     | IIIB/IV      |
|                             | 9                  | ORR, DCR | United States, China and Canada | NM         | NM                  | NM                | NM                   | NM          |
|                             | 74                 | ORR, DCR, PFS | United States, Belgium, Canada, France, Israel, Italy, Netherlands and Spain | 36       | 60                  | 66                | NM                   | NM          |
### TABLE 1 (Continued)

| Classification of treatment | Number of patients | Outcomes     | Country                                                     | Male (%) | Age, median (range) | Never-smokers (%) | Molecular diagnostics | Tumour stage |
|-----------------------------|--------------------|--------------|-------------------------------------------------------------|----------|---------------------|---------------------|----------------------|--------------|
| Humanised monoclonal antibody | 4                  | ORR, DCR     | United States                                               | 61.5     | 66 (42–82)          | NM                  | IHC, ELISA and FISH  | NM           |
|                             | 43                 | ORR, DCR, PFS| United States                                               | 60       | 62 (33–79)          | NM                  | IHC                 | NM           |
|                             | 58                 | ORR, DCR, PFS| France, Switzerland, Spain, Italy, Poland, Portugal and the Nederlands | 37.6     | 61 (30–87)          | 60.4                | PCR or NGS          | I-IV         |
| Trastuzumab-based therapy  | 13                 | ORR, DCR     | United States                                               | 61.5     | 66 (42–82)          | NM                  | IHC                 | NM           |
|                             | 53                 | ORR, DCR, PFS| United States                                               | 50.9     | 59 (52–65)          | NM                  | IHC                 | IIIb/IV, recurrent |
|                             | 51                 | ORR, DCR, PFS| United States                                               | 65.3     | 58 (35–76)          | NM                  | IHC, FISH or ELISA  | I, IIIb/IV   |
|                             | 15                 | ORR, DCR, PFS| France, Germany, Switzerland and Spain                      | 31       | 60.4 (31–86)        | 52.3                | Direct sequencing or FISH | I-IV         |
|                             | 3                  | ORR, DCR     | United States and United Kingdom                             | 51       | 62 (23–86)          | NM                  | IHC, FISH, CISH, or NGS | NM           |
| Antibody drug conjugate, DS-8201 | 42          | ORR, DCR, PFS| United States, France, Japan, Netherlands and Spain        | 35.7     | 60 (34–83)          | NM                  | NM                  | Unresectable and/or metastatic |
|                             | 18                 | ORR, DCR, PFS| Japan and United States                                     | 27.8     | 58 (23–83)          | NM                  | IHC or NGS           | NM           |
| Antibody drug conjugate, T-DM1 | 15          | ORR, DCR, PFS| Japan                                                       | 47       | 67 (45–77)          | 67                  | IHC and FISH         | IV/recurrence  |
|                             | 18                 | ORR, PFS     | United States                                               | 28       | 64 (47–74)          | 39                  | NGS, IHC or FISH     | IV/recurrence  |
|                             | 49                 | ORR, PFS     | Switzerland, United States, Poland, Spain, Germany and Italy | 59.2     | 61 (36–80)          | 20.4                | IHC                 | Advanced, recurrent, or metastatic |

**Total**: 958

**Abbreviations**: NM, not mentioned; NSCLC, non-small cell lung carcinoma; ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival; ARMS-PCR: amplification refractory mutation system-polymerase chain reaction; PCR, polymerase chain reaction; NGS, next generation sequencing; FISH, fluorescent in-situ hybridisation; CISH, chromogenic in-situ hybridisation; ICH, immunohistochemistry; ELISA, enzyme-linked immunosorbent assay.
were 22% (95% CI 11–31), 23% (95% CI 20–65), 26% (95% CI 14–39) and 16% (95% CI 6–37), while that of ADC (DS-8201) was 60% (95% CI 35–85). When restricted to the subgroup, numerically higher ORRs were observed in the pyrotinib (ORR 35%, 95% CI 12–57) and poziotinib (ORR 38%, 95% CI 19–57) groups. The details are presented in Figures 2 and 3.

### 3.4.2 | DCR

The overall DCRs of HER2-TKIs targeted therapy, humanised monoclonal antibody, trastuzumab-based treatment and ADC (T-DM1) were 59% (95% CI 49–69), 39% (95% CI 9–88), 63% (95% CI 37–89) and 31% (95% CI 4–58), respectively, while that of ADC (DS-8201) was 87% (95% CI 62–112). When restricted to the subgroup, numerically higher DCRs were observed in the pyrotinib (83%, 95% CI 60–105) and poziotinib (75%, 95% CI 56–94) groups. The details are presented in Figures 4 and 5.

### 3.4.3 | PFS

The overall median PFSs of HER2-TKIs therapy, humanised monoclonal antibody, trastuzumab-based treatment, ADC (DS-8201) and ADC (T-DM1) were 5.51 months (95% CI 3.48–7.54), 3.09 months (95% CI 0.11–6.30), 4.61 months (95% CI 2.09–7.13), 12.04 months (95% CI 9.68–14.40) and 2.65 months (95% CI 1.64–3.66), respectively. The details are presented in Figures 6 and 7.

### 3.4.4 | Publication bias

Publication bias was evaluated using funnel plots, Egger’s test and Begg’s test (Supplementary Figures S4–S6, S8–S10, S12–S14, S16–S18). The trim-and-fill method was used if publication bias was suspected. No publication bias was found in the studies.

**FIGURE 2** Forest plot of cumulative incidence of ORR among patients treated with HER2-TKIs targeted therapy
4 | DISCUSSION

In our meta-analysis, numerically higher response rates were observed in the poziotinib (ORR 37%; DCR 71%) and pyrotinib (ORR 35%; DCR 83%) groups in the subgroup analysis of HER2-TKIs therapy. Poziotinib is a new oral, irreversible inhibitor of EGFR/HER4/HER2. The molecular structure of poziotinib is smaller and more flexible than that of second- and third-generation inhibitors. Robichaux et al., Oh et al., Robichaux et al. and Socinski et al. discussed the efficacy of poziotinib in NSCLC patients with HER2 mutations. Cohort C2 of the phase II study ZENITH20 conducted by Socinski et al. evaluated the efficacy of poziotinib in NSCLC patients with HER2 alterations. This cohort was comprised of 90 patients pre-treated with HER2 exon 20 insertions. The ORR, DCR and median PFS were 35.1% (74 evaluable patients), 70% and 5.5 months, respectively. In cohort 1 of the study performed by Oh et al., ORR and DCR were 33% and 83%, respectively, in HER2 mutant lung adenocarcinoma. The survey conducted by Robichaux et al., Oh et al., Robichaux et al. and Socinski et al. discussed the efficacy of poziotinib in NSCLC patients with HER2 alterations. This cohort was comprised of 90 patients pre-treated with HER2 exon 20 insertions. The ORR, DCR and median PFS were 35.1% (74 evaluable patients), 70% and 5.5 months, respectively. In cohort 1 of the study performed by Oh et al., ORR and DCR were 33% and 83%, respectively, in HER2 mutant lung adenocarcinoma. The survey conducted by Robichaux et al. showed an ORR of 64% and DCR of 91% for poziotinib in NSCLC patients with HER2 mutations. The recommended dose of poziotinib is 16 mg daily, but 55% of the patients received a dosage reduction due to skin rash and diarrhoea. In a subsequent study, Robichaux et al. reported an ORR of 42% and a DCR of 83% in NSCLC patients with HER2 exon 20 mutation. The survey conducted by Oh et al. included patients with tumour stages I–IV, and all patients were female and non-smokers. However, the other three studies did not detail the status of smoking and the patients’ tumour stage.

Pyrotinib is an oral, irreversible pan-HER TKI inhibitor of HER2. Pyrotinib was first applied in HER2-positive breast cancer patients and obtained encouraging results. An in vitro cell proliferation assay, in which plasma concentrations of afatinib and pyrotinib were obtained from NSCLC patients with HER2 exon 20 mutations in two previous studies, showed that the inhibition of cell growth was more robust in the pyrotinib group. A phase II study of pre-treated NSCLC patients with HER2 exon 20 mutation showed a 53.3% partial response rate, 20.0% stable disease rate and a median PFS of 6.4 months. Gao et al. published a multicentre phase II study focusing on pre-treated NSCLC patients with HER2 insertion (n = 60), which showed an ORR of 31.7% and a median PFS of 6.8 months. In the same study, patients with a history of other HER2-targeted treatments or brain metastases were excluded. In our analysis, Wang et al. and Zhou et al. detailed the efficacy of pyrotinib in NSCLC patients with HER2 mutations. Wang et al. conducted a phase II study of pyrotinib in NSCLC patients with HER2 exon 20 insertion (n = 15). They reported an ORR of 53%, a DCR of 73% and a median PFS of 6.4 months (95% CI 1.60–11.20). However, Wang et al. did not detail the tumour stage nor the proportion of...
enrolled patients with each stage. In addition, pyrotinib showed a significantly more promising anti-tumour effect than afatinib in vitro ($P = .0038$) and a significantly stronger growth inhibition of organoids than afatinib ($P = .0471$) and T-DM1 ($P = .0138$) in the patient-derived xenograft (PDX) model. On the other hand, Zhou et al. included 60 patients with HER2-mutant lung adenocarcinoma of the tumour stage IIIIB or IV, who had a history of platinum-based chemotherapy. In their study, pyrotinib showed promising anti-tumour activity (ORR of 30%; DCR of 85%; median PFS of 6.9 months) and acceptable safety. In these two studies by Wang et al. and Zhou et al., all enrolled patients were diagnosed with lung adenocarcinoma, and never-smokers accounted for 67% and 71.17%, respectively. These results are consistent with those of previous studies. Male patients accounted for 53% and 45% of the participants, respectively, suggesting that molecular testing should not be restricted to females. Other concomitant mutations in the study by Zhou et al. may affect the efficacy of HER2-targeted therapy. It is important to note that these two studies lacked a control arm and had relatively small sample sizes. Nonetheless, pyrotinib showed numerically greater anti-tumour potential than chemotherapy or other licensed HER2-targeted drugs (afatinib and T-DM1) in patients with HER2 mutations. The multicentre phase II trial, which tested afatinib in 13 NSCLC patients with HER2 mutations pre-treated with platinum-based therapy, with a median PFS of 15.9 weeks and overall survival (OS) of 56 weeks, did not show the expected efficacy.

Trastuzumab is a monoclonal humanised antibody that binds to the HER2 receptor. Trastuzumab is the standard therapy for HER2-positive gastric and breast cancers and is also being examined for other HER2-positive cancers. Three studies were included in the humanised monoclonal antibody group in our analysis. The overall ORR, DCR and median PFS of humanised monoclonal antibody were 23%, 39% and 3.09 months, respectively. Lara et al. found no response to trastuzumab; Herbst et al. reported a DCR of 19% and a median PFS of 1.92 months; and Mazières et al. suggested an ORR of 52%, DCR of 76% and a median PFS of 4.8 months. In the study by Mazières et al., 57 patients were treated with trastuzumab, but one patient had T-DM1. Eight studies were included in the trastuzumab-based therapy group. A phase II trial evaluated 53 NSCLC patients with HER2 alterations. In patients with IHC 3+, the chemotherapy plus trastuzumab therapy group had a longer OS than the chemotherapy group.
FIGURE 5  Forest plot of cumulative incidence of DCR among patients treated with HER2-targeted therapy

FIGURE 6  Forest plot of PFS among patients treated with HER2-TKIs targeted therapy
51 patients were treated with trastuzumab plus gemcitabine-cisplatin, and 50 patients were treated with gemcitabine-cisplatin alone. There was no significant difference between the two groups: ORR 36% vs 41% and a median PFS of 6.1 months vs 7 months. Although ORR (83%) and median PFS (8.5 months) seemed comparatively good in the HER2 IHC 3+ trastuzumab-based group, the subgroup (n = 6) did not provide convincing information. A phase II study including 13 patients with IHC 2+ or 3+ HER2 alterations after platinum-based chemotherapy demonstrated that one patient had a partial response in the docetaxel alone group (n = 9), but none of the patients responded to the trastuzumab arm. The overall outcomes followed by combination therapy showed a partial response rate of 8% and a stable disease rate of 23%. Estimated event-free survival and OS were 4.3 months and 5.7 months, respectively. Overall, the results suggested that the efficacy of trastuzumab-based therapy was similar to or better than that of chemotherapy alone. In contrast, trastuzumab showed no response in a phase II study of pre-treated NSCLC patients with HER2 alterations.

Ado-trastuzumab emtansine, also known as T-DM1, is a HER2-targeted antibody-toxin conjugate that is made up of trastuzumab and the potent cytotoxic agent DM1. T-DM1 has a 3:4 chemotherapy drug-to-antibody ratio. Ado-trastuzumab emtansine is advocated as a treatment for NSCLC patients with HER2 mutations according to the NCCN guidelines. In a phase II study, 55% of patients with HER2 exon 20 mutations responded to T-DM1 therapy. However, another phase II study (n = 15) showed limited activity.

Trastuzumab deruxtecan, also known as T-DXd or DS-8201, is an ADC consisting of a direct HER2-targeting antibody, trastuzumab, and a cytotoxic topoisomerase inhibitor, exatecan derivative. Its mechanism of action differs from that of other ADCs. Trastuzumab deruxtecan has an 8:4 chemotherapy drug-to-antibody ratio, which improves its efficacy. Furthermore, trastuzumab deruxtecan has been reported to exert anti-tumour immune effects. Altogether, trastuzumab deruxtecan is designed to improve the characteristics of prior ADCs. In May 2020, trastuzumab deruxtecan was approved by the US Food and Drug Administration (FDA) as a breakthrough therapy for NSCLC patients with HER2 mutations after platinum-based treatment failure. The World Conference on Lung Cancer (WCLC) 2020 reported the activity of trastuzumab deruxtecan in patients with HER2 overexpression. A cohort of a phase I study enrolling NSCLC patients with HER2 overexpression or mutations had no encouraging results. However, interstitial lung disease has been reported in patients treated with DS-8201. In a phase I trial, the ORR of HER2-positive NSCLC patients was 72.7% (n = 11), whereas the median PFS was 11.3 months. The phase II trial DESTINY-Lung01, which included 90 NSCLC patients with HER2 mutations, reported an ORR of 61.9%, a DCR of 90.5% and an estimated median PFS of 14 months.

There are no published randomised controlled trials on poziotinib, pyrotinib or trastuzumab deruxtecan in patients with HER2-positive...
NSCLC. Therefore, we could not directly compare the efficacy of poziotinib, pyrotinib or trastuzumab deruxtecan with chemotherapy. However, through indirect comparison with other targeted therapies, we can deduce that the trastuzumab deruxtecan, poziotinib and pyro-
tinib treatment is superior to chemotherapy.

The definition of “HER2-positive NSCLC” is insufficient to describe the differences in the complexity of HER2 alterations. Indeed, the failure of many clinical studies focusing on HER2-targeted therapy may be due to these complex alterations. A multicentre phase II study is currently recruiting advanced NSCLC patients with HER2 overexpression (cohort 1) or mutation (cohort 2). Distinguishing between HER2 mutation and overexpression, as was done in these two cohorts, may help provide a better understanding of the influence of such alterations.

This study had several advantages. First, it is a comprehensive analysis of the efficacy of targeted therapy in HER2-positive NSCLC patients. Additionally, the studies included were of high quality. However, the limitations of this study must also be considered. First, most of the included studies were single-arm or cohort trials. Because HER2-positive cancer results from a relatively rare genetic alteration, related clinical research is fewer. Nonetheless, nearly half of the investigations consist of clinical research on new drugs. As a result, the studies included in the analysis are considered to be of relatively high quality. Second, the tumour stage and treatment lines were different in the patients included in the studies. A proportion of patients may have other concurrent gene mutations. Third, there may be differences in the exact treatment used in each study. Therefore, we considered drug classification as the grouping principle for analysis. Finally, different detection methods for HER2 alterations may influence the results. These methods are all recommended by the current guidelines, but the sensitivity and specificity of the different detection methods vary. With the enlargement of sample size and the advancement of research, subgroup analysis according to the different detection methods may be performed in the future. Nevertheless, this conclusion has a certain value and significance; but further research is warranted.

5 Conclusion
HER2-targeted therapy can be considered an acceptable treatment strategy for NSCLC patients with HER2 alterations. In particular, ADC (DS-8201), pyrotinib and poziotinib have demonstrated promising anti-tumour activity in HER2-positive NSCLC. However, further trials are required to explore new therapeutic strategies.

5.1 Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, and are permanently archived in the Concise Guide to PHARMACOLOGY 2021/22.

ACKNOWLEDGEMENTS
We thank all the people who participated in the primary trials and the teams conducted did them. This work was supported by grants from the National Natural Science Foundation of China (Grants 82070019 and 81870034).

COMPETING INTERESTS
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

OPEN RESEARCH BADGES
This article has earned Open Data, Open Materials and Preregistered Research Design badges. Data, materials and the preregistered design and analysis plan are available at https://www.crd.york.ac.uk/PROSPERO/#recordDetails.

ORCID
Ke Wang https://orcid.org/0000-0003-3934-0320

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492 Erratum in: CA Cancer J Clin. 2020;70(4):313.
2. Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice guideline update. J Clin Oncol. 2018;36(9):911-919. https://doi.org/10.1200/JCO.2017.76.7293
3. Ettinger DS, Wood DE, Aisner DL, et al. NCCN guidelines insights: non-small cell lung cancer, version 2.2021. J Natl Compr Canc Netw. 2021;19(3):254-266. https://doi.org/10.6004/jnccn.2021.0013
4. Alexander SP, Kelly E, Marrion N, et al. The Concise Guide to PHARMACOLOGY 2019/20: Catalytic receptors. Br J Pharmacol. 2019;176:51-S20. https://doi.org/10.1111/bph.14747
5. Alexander SP, Kelly E, Marrion NV, et al. The Concise Guide to PHARMACOLOGY 2019/20: Introduction and other protein targets. Br J Pharmacol. 2019;176:51-S20. https://doi.org/10.1111/bph.14796
6. Pillai RN, Behera M, Berry LD, et al. HER2 mutations in lung adenocarcinomas: a report from the Lung Cancer Mutation Consortium. Cancer. 2017;123(21):4099-4105. https://doi.org/10.1002/cncr.30869
7. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Association of HER-2 overexpression with prognosis in non small cell lung carcinoma: a meta analysis. Cancer. 2005;103(9):1865-1873. https://doi.org/10.1002/cncr.20957
8. Chmielecki J, Ross JS, Wang K, et al. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. Oncologist. 2015;20(1):7-12. https://doi.org/10.1634/theoncologist.2014-0234
10. The Clinical Knowledgebase. Erbb2 gene level evidence; 2020. https://ckb.jax.org

11. Arcila ME, Chaft JE, Nafa K, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012;18(18):4910-4918. https://doi.org/10.1158/1078-0432.CCR-12-0912

12. Sassen A, Rochon J, Wild P, et al. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res. 2008;10(1):R2. https://doi.org/10.1186/bcr1843

13. Li BT, Ross DS, Aisner DL, et al. HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers. J Thorac Oncol. 2016;11(3):414-419. https://doi.org/10.1016/j.jtho.2015.10.025

14. Kim EK, Kim KA, Lee CY, Shim HS. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma. PLoS ONE. 2017;12(2):e0171280. https://doi.org/10.1371/journal.pone.0171280

15. Garrido-Castro AC, Felió E. HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches. Transl Lung Cancer Res. 2013;2(2):122-127. https://doi.org/10.3978/j.issn.2218-6751.2013.02.02

16. Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA Jr. HER2/neu expression in malignant lung tumors. Semin Oncol. 2002;29(1 Suppl 4):S1-S8. https://doi.org/10.1053/socn.2002.31523

17. Heinmöller P, Gross C, Beyser K, et al. HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin. Clin Cancer Res. 2003;9(14):5238-5243. https://doi.org/10.1158/1078-0432.CCR-01-0666-3

18. Zhao J, Xia Y. Targeting HER2 alterations in non-small-cell lung cancer: a comprehensive review. JCO Precis Oncol. 2020;4(4):e1-425. https://doi.org/10.1200/PPO.19.00333

19. Zinner RG, Glisson BS, Bossella FV, et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer. 2004;44(1):99-110. https://doi.org/10.1016/j.lungcan.2003.09.026

20. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone as first-line treatment for patients with HER2-positive, advanced, metastatic breast cancer: a randomized phase III study of Her2-overexpressing, metastatic breast cancer. J Clin Oncol. 2005;23(16):3997-4005. https://doi.org/10.1200/JCO.2004.05.004

21. Wang X, Hu W, Xie L. Response to anti-HER2-based treatment in a patient with bladder adenocarcinoma harboring HER2 amplification and S210F mutation discovered by next-generation sequencing: a case report. Onco Targets Ther. 2020;13:4249-4255. https://doi.org/10.2147/OTT.S247515

22. Yoshizawa A, Sumiyoshi S, Sonobe M, et al. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations. Lung Cancer. 2014;85(3):373-378. https://doi.org/10.1016/j.lungcan.2014.06.007

23. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097

24. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.3.0. Oxford: The Cochrane Collaboration; 2014. Accessed 30 May 2021. http://www.cochrane-handbook.org, Updated March 2014.

25. Cota GF, de Sousa MR, Fereguetti TO, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Accessed May 30, 2021. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
open-label, single-arm, phase II study. J Clin Oncol. 2020;38(24):2753-2761. https://doi.org/10.1200/JCO.20.00297

42. Zhou J, Ding N, Xu X, et al. Clinical outcomes of patients with HER2-mutant advanced lung cancer: chemotherapies versus HER2-directed therapies. Ther Adv Med Oncol. 2020;12:1758835920936090. https://doi.org/10.1177/1758835920936090

43. Liu SV, Villaruz LC, Lee VHF, et al. First analysis of RAIN-701: study of tarexotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions. Ann Oncol. 2020;31:S1189. https://doi.org/10.1016/j.annonc.2020.08.2294

44. Sociński M, Cornelissen R, Garassino M, et al. LBA60 ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations. Ann Oncol. 2020;31:S1188. https://doi.org/10.1016/j.annonc.2020.08.2293

45. Lara PN Jr, Laptalo L, Longmate J, et al. Neratinib-based combination therapy in breast cancer. J Thorac Oncol. 2018;13(20):2175-2181. https://doi.org/10.1016/j.jtho.2018.07.018

46. Gatzemeier U, Groth G, Butts C, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol. 2004;15(1):19-27. https://doi.org/10.1093/annonc/mdh031

47. Hainsworth JD, Meric-Bernstam F, Swanton C, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018;36(6):536-542. https://doi.org/10.1200/JCO.2017.75.3780 Erratum in: J Clin Oncol. 2019;37(4):360

48. Gao G, Li X, Wang Q, et al. Single-arm, phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER2 in pretreated patients with HER2 positive tumors. Ann Oncol. 2004;15(1):19-27. https://doi.org/10.1093/annonc/mdh031

49. Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH. Trastuzumab in the treatment of advanced non-small cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group Study 2598. J Clin Oncol. 2004;22(7):1180-1187. https://doi.org/10.1200/JCO.2004.04.105

50. de Langen AJ, Jebbink M, Hashemi SMS, et al. Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2. JCO.2017.120.3615-362. https://doi.org/10.1016/j.jtho.2017.12.003

51. Li B, Gandhi L, Besse B, et al. Neratinib-based combination therapy in HER2-mutant non-small cell lung cancer. J Thorac Oncol. 2018;13(20):2175-2181. https://doi.org/10.1016/j.jtho.2018.07.018

52. Smit EF, Nakagawa K, Nagasaka M, et al. Discovery and development of pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharm Sci. 2017;110:51-61. https://doi.org/10.1016/j.ejps.2017.01.021

53. Li Y, Yang C, Wan H, et al. Discovery and development of pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2017;35(27):3105-3112. https://doi.org/10.1200/JCO.2016.69.6179

54. Li B, Gandhi L, Besse B, et al. Neratinib-based combination therapy in HER2-mutant non-small cell lung cancer. J Thorac Oncol. 2018;13(20):2175-2181. https://doi.org/10.1016/j.jtho.2018.07.018

55. Li B, Gandhi L, Besse B, et al. Neratinib-based combination therapy in HER2-mutant non-small cell lung cancer. J Thorac Oncol. 2018;13(20):2175-2181. https://doi.org/10.1016/j.jtho.2018.07.018

56. Peters S, Stahel R, Bubendorf L, et al. Trastuzumab emtansine (T-DM1) in patients with previously treated HER2-overexpressing metastatic non-small cell lung cancer: efficacy, safety, and biomarkers. Clin Cancer Res. 2019;25(1):64-72. https://doi.org/10.1186/1078-0432.CCR-18-1590

57. Cha MY, Lee KO, Kim M, et al. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 2012;130(10):2445-2454. https://doi.org/10.1002/ijc.26276

58. Li X, Yang C, Wan H, et al. Discovery and development of pyrotinib: a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharm Sci. 2017;110:51-61. https://doi.org/10.1016/j.ejps.2017.01.021
